Bangkok Genomics Innovation PCLBKK:BKGI +4.76%45 Gross Margin % is 41.78% as of Dec. 2025, which is 3% below its 10-year median of 42.91. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks worse than 61.22% on this metric.
BKK:BKGI's Gross Margin % is ranked worse than 61.22% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs BKK:BKGI: 41.01
Bangkok Genomics Innovation PCL had a gross margin of 41.78% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bangkok Genomics Innovation PCL had a gross margin of 41.78% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bangkok Genomics Innovation PCL Gross Margin % Related Terms
Bangkok Genomics Innovation PCL Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Gross Margin % of 41.78% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is near median its historical median of 42.91. Over the past decade, Bangkok Genomics Innovation PCL's Gross Margin % has ranged from 29.81 to 51.68. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #120 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 61.2%.
Is Bangkok Genomics Innovation PCL's Gross Margin % too high?
Bangkok Genomics Innovation PCL's current Gross Margin % of 41.78% is near median its 10-year median of 42.91. Over the past 10 years, this metric has ranged from a low of 29.81 to a high of 51.68. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Bangkok Genomics Innovation PCL's value of 41.78% is 18.3% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #120 out of 196 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #120 out of 196 companies for Gross Margin %. This places Bangkok Genomics Innovation PCL in the lower half of its industry. The industry median Gross Margin % is 51.14. Bangkok Genomics Innovation PCL's value of 41.78% is 18.3% below this benchmark. Historically, Bangkok Genomics Innovation PCL's own Gross Margin % has ranged from 29.81 to 51.68 over the past decade. While the company's 10-year median is 42.91 vs. the industry median of 51.14, Bangkok Genomics Innovation PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current Gross Margin % of 41.78% is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current Gross Margin % is 41.78%, which is near median its own 10-year median of 42.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Gross Margin % of 41.78%. The current Gross Margin % is 41.78%, which is near median its 10-year median of 42.91 and 18.3% below the Medical Diagnostics & Research industry median of 51.14. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Gross Margin % is 41.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
